Elevated MSI2 expression is considered a biomarker of poor outcome in multiple hematological diseases, such as chronic myeloid leukemia (CML), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and chronic lymphocytic leukemia (CLL)14,15,19,51–53. This evidence concerns the gene MSI2 and myelodysplastic syndrome.